UnitedHealth Group (UNH) Q3 2026 Earnings: What Investors Should Watch
Key Takeaways
- UnitedHealth Group (UNH) is scheduled to report third quarter 2026 results before the market opens on Tuesday, October 13, 2026.
- Analysts expect adjusted earnings of roughly $4.12 per share, up sharply from $2.92 in the prior-year quarter.
- Consensus revenue sits near $111.3 billion, reflecting a modest year-over-year decline tied to ongoing portfolio right-sizing.
- The company has beaten Wall Street's earnings estimates in each of its last four quarterly reports.
- Investors will focus on the medical care ratio, Medicare Advantage enrollment trends, and any update to full-year guidance.
Earnings Context and Why It Matters
UnitedHealth Group's quarterly report serves as an important indicator for the managed-care and healthcare-services sector overall. As the largest health insurer in the country, its numbers provide early insights into medical cost trends, Medicare Advantage dynamics, and the effects of Medicaid redeterminations that affect the broader industry. The company approaches this report after a solid stretch, having exceeded consensus estimates in four consecutive quarters while improving margins. With full-year adjusted earnings guidance already lifted to a range of $19.50 to $20.00 per share back in July, this quarter will show whether cost controls and pricing efforts can maintain that progress through the end of the year.
Earnings Expectations
Wall Street anticipates UnitedHealth will post third quarter 2026 adjusted earnings of about $4.12 per share, based on consensus figures from sources such as Zacks and MarketBeat, though some forecasts edge closer to $4.15. This marks a notable increase from $2.92 per share in the same quarter last year, representing growth of more than 40%. Revenue expectations stand at approximately $111.3 billion, which would represent a decline of about 1.6% from $113.2 billion a year earlier due to the company's intentional reduction in certain lower-margin segments.
For additional perspective, UnitedHealth posted adjusted earnings of $6.38 per share on $112.0 billion in revenue during the second quarter of 2026, surpassing estimates by a comfortable margin and lifting the shares roughly 7.6% in premarket trading. The full-year 2026 adjusted earnings outlook remains $19.50 to $20.00 per share following the earlier upward revision. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
Market Reaction and Investor Sentiment
Investor sentiment ahead of the report appears measured and generally positive. Analysts maintain a largely bullish stance on UNH, with most assigning a Buy rating and price targets sitting comfortably above recent trading levels. There is confidence that third-quarter medical cost and earnings targets remain attainable, with some highlighting potential upside from the Optum Health segment. Potential risks include medical cost inflation, continued attrition in Medicare Advantage membership, and ongoing pressure on Medicaid margins, which management has described as still negative. Options activity suggests traders anticipate a noticeable move after the release, consistent with the stock's past patterns around earnings.
Forward Outlook and Key Factors to Monitor
Outside the headline numbers, several operating details deserve close attention. The medical care ratio, which tracks medical costs relative to premium revenue, improved to 86.7% in the second quarter from 89.4% a year earlier. A stable or better reading here would reinforce the margin-expansion story.
Enrollment trends matter as well. UnitedHealthcare has been intentionally reducing its Medicare Advantage and Medicaid membership, with prior guidance pointing to a potential decline of roughly 1.1 million Medicare Advantage members for the year. Investors will seek signs that this right-sizing effort is leveling off and that pricing measures are effectively offsetting the lost members.
Within Optum, focus will turn to Optum Health's value-based care progress and Optum Rx's shift toward a transparent, fee-based pharmacy approach. Both areas support longer-term growth plans.
Guidance updates will carry particular weight. With the company already targeting full-year adjusted earnings of $19.50–$20.00 per share, any adjustment could influence the post-earnings stock move. Commentary on 2027 Medicare Advantage star ratings and their revenue implications will also receive careful review.
Exploring AI Tools for Earnings Research
From what I see, incorporating data-driven tools has become a practical part of staying ahead of earnings seasons. I recently turned to Tickeron's AI Screener to scan for comparable healthcare names and review technical setups around upcoming reports. The platform allows filtering by fundamentals, patterns, and signals, which helps surface ideas efficiently when preparing for events like this one. It has proven useful for identifying context without replacing traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
UNH's Indicator enters downward trend
The Aroon Indicator for UNH entered a downward trend on October 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 123 similar instances where the Aroon Indicator formed such a pattern. In 83 of the 123 cases the stock moved lower. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 63 cases where UNH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UNH's RSI Indicator exited the oversold zone, 27 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UNH as a result. In 45 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 54%.
The Moving Average Convergence Divergence (MACD) for UNH just turned positive on October 05, 2026. Looking at past instances where UNH's MACD turned positive, the stock continued to rise in 26 of 46 cases over the following month. The odds of a continued upward trend are 57%.
Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.445) is normal, around the industry mean (3.247). P/E Ratio (24.282) is within average values for comparable stocks, (139.958). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 57 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 99 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement